Navin Fluorine to meet with Analysts/Investors on September 15-16, 2025
Meetings with analysts and investors can influence market perception. Strong Q1 results also contribute to a medium impact.
The announcement discusses a meeting with analysts/investors and includes positive financial results for Q1FY26, indicating a positive outlook.
* Navin Fluorine International Limited will interact with analysts and investors on a group basis on September 15 and 16, 2025. * The discussion will be based on publicly available information, and the presentation has been enclosed. * Q1FY26 Consolidated Financials: * Sales: ₹725.4 crore, up 39% Y-o-Y. * Operating EBITDA: ₹206.8 crore, up 106% Y-o-Y. * Operating EBITDA Margin: 28.5% (+935 bps Y-o-Y). * Operating PBT: ₹141.2 crore, up 143% Y-o-Y. * Business Vertical - HPP: * Q1 FY26 Revenue ₹281 crore, +45% Y-o-Y, led by higher realizations and volumes. The pricing landscape for refrigerant gases remains firm. * AHF capex for ₹450 crore at Dahej is expected to commission by the end of Q2 FY26. * R32 plant commercialized in March 2025 running at optimum utilization. * Business Vertical - Specialty Chemicals: * Q1 FY26 Revenue ₹219 crore, +35% Y-o-Y. Optimal capacity utilization at Dahej & Surat with a strong order book for FY26. * Strategic Partnership with Chemours and foray into High-Growth Advanced Materials. * Supplies for 3 new molecules to start in Q2FY26; Orders are in place. * Business Vertical - CDMO: * Q1 FY26 Revenue ₹99 crore, +23% Y-o-Y. Strong revenue visibility backed by a robust order book for FY26. * cGMP 4 capex for ₹288 crore – Phase 1 capex of ₹160 crore on track to commission by the end of Q3FY26. * EU Major – Material order received for supply in Q2FY26. * Another EU Major – Scale-up order expected in Q2FY26. * US Major – Commercial order expected for delivery in FY26 (Scale -up order delivered). * European CDMO MSA: Molecule approved by US & EU for expanded application is encouraging. * Total R&D spend in FY25: ₹54.69 crore.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.